CN105434465B - 一种防治关节炎的药物组合物及其制备方法 - Google Patents

一种防治关节炎的药物组合物及其制备方法 Download PDF

Info

Publication number
CN105434465B
CN105434465B CN201510926291.1A CN201510926291A CN105434465B CN 105434465 B CN105434465 B CN 105434465B CN 201510926291 A CN201510926291 A CN 201510926291A CN 105434465 B CN105434465 B CN 105434465B
Authority
CN
China
Prior art keywords
preparation
purposes
drug
inorganic compound
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510926291.1A
Other languages
English (en)
Other versions
CN105434465A (zh
Inventor
米军
刘紫鹃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Anpro Biotechnology Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510926291.1A priority Critical patent/CN105434465B/zh
Publication of CN105434465A publication Critical patent/CN105434465A/zh
Priority to PCT/CN2016/099076 priority patent/WO2017101536A1/zh
Priority to US15/544,641 priority patent/US10485826B2/en
Application granted granted Critical
Publication of CN105434465B publication Critical patent/CN105434465B/zh
Priority to US16/694,408 priority patent/US20200085863A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明公开了一种防治关节炎的药物组合物，它是由下述原料药制备而成的制剂：含硒无机化合物、含锌无机化合物。所述的药物组合物可制备成外用制剂，针对各种关节疼痛提供了更为快速、安全的治疗手段。药效实验证明，本发明药物组合物可以显著降低关节炎模型的关节冲洗液中炎性细胞因子的水平，其软膏剂甚至能达到优于扶他林软膏的疗效，具有良好的临床应用前景。

Description

一种防治关节炎的药物组合物及其制备方法
技术领域
本发明涉及一种防治关节炎的药物组合物及其制备方法，属于医药领域。
背景技术
关节炎泛指发生在人体关节及其周围组织的炎性疾病，可分为数十种。其中最常见的骨关节炎是一种退行性关节病变，另外还有诸如风湿性关节炎、类风湿关节炎、痛风性关节炎等多种类型。这类疾病的病因尚不完全明确，临床表现近似，以关节的红、肿、热、痛、功能障碍及关节畸形为主要症状，常用的抗炎药物主要为非甾体抗炎药，包括布洛芬、阿司匹林、双氯芬酸等，其中以双氯酚酸二乙胺为主要活性成份的扶他林软膏应用较为广泛。然而，对胃肠道粘膜的刺激作用大大限制了这类药物在临床上的应用，因此亟需开发出疗效显著、副作用小的替代药物。
硒和锌都是人和动物机体不可缺少的微量元素，在生理活动中发挥着重要作用。在中国的某些地方，硒缺乏导致地方病的发生。例如青藏高原人群的饮食中缺乏硒，这些人更患大骨节病的风险很高。含硒无机物的典型代表为亚硒酸钠，国内外已有多家制药企业生产亚硒酸钠的片剂，用以治疗和预防属于地方病的克山病和大骨节病；CN 1511541A、CN1679622A还公开了以亚硒酸钠为活性成份制备的片剂、颗粒剂、胶囊剂和口服液在制备治疗骨性关节炎、类风湿性关节炎的药物中的用途。另外，目前临床上使用较为普遍的含锌无机物以氯化锌为代表，常制备成软膏剂，用于治疗急性或亚急性皮炎、湿疹、痱子及轻度、小面积的皮肤溃疡。
然而，迄今尚未见将含硒无机物、含锌无机物组合使用，用于治疗关节炎的报道。
发明内容
本发明的目的在于提供一种防治关节炎的药物组合物，以解决现有药物疗效不佳、药物需口服、刺激胃肠道粘膜产生不良反应的问题。
本发明提供了一种防治关节炎的药物组合物，它是由下述原料药制备而成的制剂：含硒无机化合物、含锌无机化合物。
进一步的，它是由下述重量配比的原料药制备而成的制剂：含锌无机化合物1份～5份、含硒无机化合物1份～5份。
优选的，它是由下述重量配比的原料药制备而成的制剂：含锌无机化合物3份、含硒无机化合物3份。
进一步的，所述的含锌无机化合物选自硫酸锌、氯化锌或乙酸锌中的一种或几种；所述的含硒无机化合物为亚硒酸钠。
其中，所述的制剂由各重量配比的原料药，加上药学上可接受的辅料或辅助性成份制备而成。
进一步的，所述的制剂为外用制剂。
优选的，所述的制剂选自凝胶剂、乳膏剂、软膏剂或贴剂。
本发明提供了一种所述的药物组合物的制备方法，其特征是：包含下述步骤：称取各重量配比的原料药，加入药学上可接受的辅料或辅助性成份，即得。
本发明还提供了所述的药物组合物在制备治疗和/或预防关节炎的药物中的用途。
进一步的，所述的药物是治疗和/或预防骨关节炎、风湿性关节炎、类风湿关节炎、痛风性关节炎、反应性关节炎、感染性关节炎、创伤性关节炎、腕管综合症、粘液囊炎中一种或几种疾病的药物。
优选的，所述的药物是治疗和/或预防骨关节炎的药物。
本发明提供了一种防治关节炎的药物组合物。该药物组合物可制备成外用制剂，针对各种关节疼痛提供了更为快速、安全的治疗手段。虽然硒盐对关节炎症具有一定的治疗效果，但是无机硒盐外用很难转运到炎性细胞内，而本发明药物组合物巧妙地解决了这个问题。药效实验证明，本发明药物组合物可以显著降低关节炎模型的关节冲洗液中炎性细胞因子的水平，其软膏剂甚至能达到优于扶他林软膏的疗效，具有良好的临床应用前景。
显然，根据本发明的上述内容，按照本领域的普通技术知识和惯用手段，在不脱离本发明上述基本技术思想前提下，还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式，对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
本发明具体实施方式中使用的原料、设备均为已知产品，通过购买市售产品获得。
实施例1本发明药物组合物凝胶剂的制备
处方：硫酸锌0.10g，亚硒酸钠0.10g，卡波姆94010g，甘油75g，聚山梨酯802g，三乙醇胺13.5g，蒸馏水加至1000g。
工艺：将卡波姆940与聚山梨酯80及300g蒸馏水混合，另取三乙醇胺溶于100g蒸馏水后加入前述溶液中搅匀，再加入甘油搅匀，即得基质。取硫酸锌和亚硒酸钠溶于蒸馏水250g中，全溶后加入上述基质中，加水至全量,搅拌均匀，除去气泡，即得凝胶剂ZJ-1。
实施例2本发明药物组合物凝胶剂的制备
处方：硫酸锌0.5g，亚硒酸钠0.1g，卡波姆94010g，甘油75g，聚山梨酯802g，三乙醇胺13.5g，蒸馏水加至1000g。
工艺：将卡波姆940与聚山梨酯80及300g蒸馏水混合，另取三乙醇胺溶于100g蒸馏水后加入前述溶液中搅匀，再加入甘油搅匀，即得基质。取硫酸锌和亚硒酸钠溶于蒸馏水250g中，全溶后加入上述基质中，加水至全量,搅拌均匀，除去气泡，即得凝胶剂ZJ-2。
实施例3本发明药物组合物乳膏剂的制备
处方：硫酸锌0.5g，亚硒酸钠0.5g,白凡士林100g，十八醇100g，液体石蜡50g，单硬脂酸甘油酯60g，OP乳化剂(烷基酚聚氧乙烯醚)10g，平平加O 20g，甘油50g，月桂氮卓酮20g。
工艺：取白凡士林，十八醇，单硬脂酸甘油酯，液体石蜡，平平加O，混合，加热至80度溶解，得油相。取氯化锌，月桂氮卓酮，亚硒酸钠，甘油，OP乳化剂加水300ml，搅拌均匀，加入油相，保温乳化20分钟，加水至1000ml，即得乳膏剂ZJ-3。
实施例4本发明药物组合物软膏剂的制备
处方：硫酸锌0.1g，亚硒酸钠0.5g，硬脂酸120g，单硬脂酸甘油酯30g，液体石蜡50g，凡士林12g，羊毛脂40g，三乙醇胺3g，尼泊金乙酯1g，加蒸馏水至1000g。
工艺：取硬脂酸、单硬脂酸甘油酯、液体石蜡、凡士林、羊毛脂混合加热熔化；另取硫酸锌和亚硒酸钠、三乙醇胺、尼泊金乙酯、加蒸馏水，加热混匀，慢慢倒入前述硬脂酸等的混合物中，搅拌至乳化凝结，即得软膏剂ZJ-4。
实施例5本发明药物组合物贴剂的制备
处方：硫酸锌0.3g，亚硒酸钠0.3g，明胶60g，纤维素钠100g，聚丙烯酸钠30g，高岭土120g，PEG400(聚乙二醇400)80g，卡波姆100g，山梨醇20g，甘油200g，水290g。
工艺：取各原辅料，混合，搅拌均匀，加无纺布，背衬层，防粘层，即得贴剂ZJ-5。
实施例6本发明药物组合物凝胶剂的制备
处方：氯化锌0.5g，亚硒酸钠0.1g，卡波姆94010g，甘油75g，聚山梨酯802g，三乙醇胺13.5g，蒸馏水加至1000g。
工艺：将卡波姆940与聚山梨酯80及300g蒸馏水混合，另取三乙醇胺溶于100g蒸馏水后加入前述溶液中搅匀，再加入甘油搅匀，即得基质。取硫酸锌和亚硒酸钠溶于蒸馏水250g中，全溶后加入前述基质中，加水至全量，搅拌均匀，除去气泡，即得凝胶剂ZJ-6。
实施例7本发明药物组合物凝胶剂的制备
处方：乙酸锌0.3g，亚硒酸钠0.3g，卡波姆9405g，甘油75g，聚山梨酯802g，三乙醇胺13.5g，蒸馏水加至1000g。
工艺：将卡波姆940与聚山梨酯80及60g蒸馏水混合，另取三乙醇胺溶于100g蒸馏水后加入前述溶液搅匀，再加入甘油搅匀，即得基质。取硫酸锌和亚硒酸钠溶于蒸馏水50g中，全溶后加入前述基质中，加水至全量，搅拌均匀，除去气泡，即得凝胶剂ZJ-7。
实施例8本发明药物组合物乳膏剂的制备
处方：氯化锌0.1g，亚硒酸钠0.5g，白凡士林100g，十八醇100g，液体石蜡50g，单硬脂酸甘油酯60g，OP乳化剂10g，平平加O 20g，甘油50g，月桂氮卓酮20g。
工艺：取白凡士林，十八醇，单硬脂酸甘油酯，液体石蜡，平平加O，混合，加热至80度溶解，得油相，取氯化锌，月桂氮卓酮，亚硒酸钠，甘油，OP乳化剂加水300ml，搅拌均匀，加入油相，保温乳化20分钟，加水至1000ml，即得乳膏剂ZJ-8。
以下通过对比例和药效实验证明本发明的有益效果。
对比例1锌凝胶剂的制备
处方：硫酸锌0.5g，卡波姆94010g，甘油75g，聚山梨酯802g，三乙醇胺13.5g，蒸馏水加至1000g。
工艺：将卡波姆940与聚山梨酯80及300g蒸馏水混合，另取三乙醇胺溶于100g蒸馏水后加入前述溶液搅匀，再加入甘油搅匀，即得基质。取硫酸锌和亚硒酸钠溶于蒸馏水250g中，全溶后加入前述基质中，加水至全量，搅拌均匀，除去气泡，即得锌凝胶剂ZN。
对比例2硒凝胶剂的制备
处方：亚硒酸钠0.5g，卡波姆94010g，甘油75g，聚山梨酯802g，三乙醇胺13.5g，蒸馏水加至1000g。
工艺：将卡波姆940与聚山梨酯80及300g蒸馏水混合，另取三乙醇胺溶于100g蒸馏水后加入前述溶液搅匀，再加入甘油搅匀，即得基质。取硫酸锌和亚硒酸钠溶于蒸馏水250g中，全溶后加入上述基质中，加水至全量，搅拌均匀，除去气泡，即得硒凝胶剂SE。
药效实验
炎症的常规生物标记物是细胞因子和趋化因子如TNF-α(肿瘤坏死因子-α)、NF-kB(转录因子蛋白家族)或IL(白介素)等。
实验目的：考察本发明药物组合物对兔膝骨关节炎模型中细胞因子(TNF-α和IL-1β)含量的影响。
材料与方法：
实验材料：实验动物健康新西兰大白兔130只，雌雄各半，体重2.5-3Kg，由成都达硕实验动物有限公司提供。标准饲料喂养，室温15～25℃，每天正常光照，空气流通，自由摄食、饮水。
实验药品：
根据实施例1～8制备的制剂对照药物：扶他林软膏
主要试剂及仪器：
TNF-α放免测定试剂盒；
IL-1β放免测定试剂盒；
电子天平(ME2355型，SARTORIUS公司)，系列可调节移液器及吸头、低速离心机、快速混匀器、兔固定台，冰箱等。
实验方法：
动物分组：130只新西兰大白兔采用单纯随机抽样方法分为13组：空白组、模型组、对照组、ZN组、SE组、治疗组1-8组，每组10只，称重标记。
造模方法：除空白组不造模外，其余12组采用Vandman法将实验动物左膝关节用石膏固定于伸直位。固定范围从兔踝关节下3cm至腹股沟以下1.5cm，踝背屈30-40°，固定时间6周。固定满6周后，将各组动物分别随机处死1只，取关节软骨作病理检查以观察造模情况。造模成功后，去除固定，剃毛。
给药：各组造模成功后，对照组外涂扶他林软膏，厚度约2mm，均匀覆盖造模关节表面，每天2次。治疗组分别外用根据实施例1～8制备的制剂，厚度约2mm，均匀覆盖造模关节表面，每天2次。ZN组外用根据对比例1制备的凝胶剂，SE组外用根据对比例2制备的凝胶剂，厚度约2mm，均匀覆盖造模关节表面，每天2次。模型组外敷凡士林，厚度约2mm，均匀覆盖造模关节，每天2次。空白组亦于右膝关节表面外敷凡士林，厚度约2mm，每天2次。
检测方法：
敷药8周后耳缘静脉处注射空气30ml，快速处死兔，固定于解剖架上，双膝关节快速备皮消毒；取髌韧带附着点外上方约0.5cm处，沿韧带外缘向内向后进针，向关节腔内注射1.5ml蒸馏水，反复吸抽关节液数次后，抽取约2ml关节混合液，将关节混合液置4000r/min离心10min，吸出上清液约0.3ml，装入试管中，置-20℃低温冰箱保存待测，关节冲洗液中TNF-α和IL-1β含量按试剂盒内含量按试剂盒内说明书进行测定。
统计学方法：
实验数据以平均值±标准差(x±s)表示，采用t或t’检验进行组间两两比较，检验水准α＝0.05，运用SPSS 17.0软件进行分析。
实验结果
表1 本发明药物组合物对兔膝骨关节炎模型关节液中细胞因子TNF-α和IL-1β含量的影响
空白组关节冲洗液中TNF-α、IL-1β含量低于模型组，有显著性差异(P<0.01)，说明造模后兔左膝关节液中炎性细胞因子增高。
对照组、治疗组关节冲洗液中TNF-α、IL-1β含量比模型对照组低，有显著性差异(P<0.01)，说明本发明药物组合物可以显著降低关节炎模型的关节冲洗液中炎性细胞因子的水平。
单用含硒凝胶剂或者单用含锌凝胶剂，关节冲洗液中TNF-α、IL-1β含量与模型组相比无显著性差异，说明单用硒或锌治疗关节炎的抗炎效果较差，而仅有本发明含硒无机物、含硒无机物在特定配比下组合使用，才能达到理想的抗炎效果。
以上实验结果表明：本发明药物组合物对关节炎具有显著的治疗效果，其中贴剂ZJ-5甚至能达到明显优于扶他林软膏的疗效。

Claims (7)

1.下述药物组合物在制备治疗和/或预防关节炎的药物中的用途，所述药物组合物是由下述重量配比的原料药制备而成的制剂：含锌无机化合物3份、含硒无机化合物3份。
2.如权利要求1所述的用途，其特征是：所述的含锌无机化合物选自硫酸锌、氯化锌或乙酸锌中的一种或几种；所述的含硒无机化合物为亚硒酸钠。
3.如权利要求1-2任意一项所述的用途，其特征是：所述的制剂由各重量配比的原料药，加上药学上可接受的辅料或辅助性成份制备而成。
4.如权利要求3所述的用途，其特征是：所述的制剂为外用制剂。
5.如权利要求4所述的用途，其特征是：所述的制剂选自凝胶剂、乳膏剂、软膏剂或贴剂。
6.如权利要求1所述的用途，其特征是：所述的药物是治疗和/或预防骨关节炎、风湿性关节炎、类风湿关节炎、痛风性关节炎、反应性关节炎、感染性关节炎、创伤性关节炎、腕管综合症、粘液囊炎中一种或几种疾病的药物。
7.如权利要求6所述的用途，其特征是：所述的药物是治疗和/或预防骨关节炎的药物。
CN201510926291.1A 2015-12-14 2015-12-14 一种防治关节炎的药物组合物及其制备方法 Active CN105434465B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201510926291.1A CN105434465B (zh) 2015-12-14 2015-12-14 一种防治关节炎的药物组合物及其制备方法
PCT/CN2016/099076 WO2017101536A1 (zh) 2015-12-14 2016-09-14 一种防治关节炎的药物组合物及其制备方法
US15/544,641 US10485826B2 (en) 2015-12-14 2016-09-14 Pharmaceutical formula for the treatment and/or prevention of arthritis and its manufacture
US16/694,408 US20200085863A1 (en) 2015-12-14 2019-11-25 Pharmaceutical formula for the treatment and/or prevention of arthritis and its manufacture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510926291.1A CN105434465B (zh) 2015-12-14 2015-12-14 一种防治关节炎的药物组合物及其制备方法

Publications (2)

Publication Number Publication Date
CN105434465A CN105434465A (zh) 2016-03-30
CN105434465B true CN105434465B (zh) 2019-07-16

Family

ID=55545399

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510926291.1A Active CN105434465B (zh) 2015-12-14 2015-12-14 一种防治关节炎的药物组合物及其制备方法

Country Status (3)

Country Link
US (2) US10485826B2 (zh)
CN (1) CN105434465B (zh)
WO (1) WO2017101536A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021262230A1 (en) * 2020-06-26 2021-12-30 The Procter & Gamble Company Azoxystrobin in a sulfate free personal care composition
US12226505B2 (en) 2018-10-25 2025-02-18 The Procter & Gamble Company Compositions having enhanced deposition of surfactant-soluble anti-dandruff agents

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105434465B (zh) * 2015-12-14 2019-07-16 米军 一种防治关节炎的药物组合物及其制备方法
EP3989921A1 (en) 2019-06-28 2022-05-04 The Procter & Gamble Company Synergistic anti-inflammatory compositions
EP4171755A1 (en) 2020-06-26 2023-05-03 The Procter & Gamble Company Synergistic anti-inflammatory compositions
US11701316B2 (en) 2020-12-18 2023-07-18 The Procter & Gamble Company Synergistic anti-inflammatory compositions
CN113854571A (zh) * 2021-09-29 2021-12-31 山东大学齐鲁医院 硒制剂在制备股骨头坏死性疾病保健食品、药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1166963A (zh) * 1997-03-17 1997-12-10 夏小琳 含有锌化合物和对乙酰氨基苯乙酸的组合物
CN1511541A (zh) * 2002-12-30 2004-07-14 胡锦心 亚硒酸钠在制药中的应用
CN1679622A (zh) * 2002-12-30 2005-10-12 胡锦心 亚硒酸钠在制备骨性关节炎药物中的应用
CN102940284A (zh) * 2012-09-01 2013-02-27 山东博然螺旋藻生物股份有限公司 一种富锌速溶螺旋藻的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2260856A1 (en) * 2009-05-12 2010-12-15 URSAPHARM Arzneimittel GmbH Immune stimulating composition comprising an extract of aronia sp. in combination with selenium and/or zinc
CN101934016B (zh) * 2010-08-31 2012-03-07 胡枝清 一种治疗关节炎的外用药
CN105434465B (zh) * 2015-12-14 2019-07-16 米军 一种防治关节炎的药物组合物及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1166963A (zh) * 1997-03-17 1997-12-10 夏小琳 含有锌化合物和对乙酰氨基苯乙酸的组合物
CN1511541A (zh) * 2002-12-30 2004-07-14 胡锦心 亚硒酸钠在制药中的应用
CN1679622A (zh) * 2002-12-30 2005-10-12 胡锦心 亚硒酸钠在制备骨性关节炎药物中的应用
CN102940284A (zh) * 2012-09-01 2013-02-27 山东博然螺旋藻生物股份有限公司 一种富锌速溶螺旋藻的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
微量元素与类风湿关节炎;马亚兵 等;《食品与药品》;20101231;第12卷(第05期);224-226

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226505B2 (en) 2018-10-25 2025-02-18 The Procter & Gamble Company Compositions having enhanced deposition of surfactant-soluble anti-dandruff agents
WO2021262230A1 (en) * 2020-06-26 2021-12-30 The Procter & Gamble Company Azoxystrobin in a sulfate free personal care composition

Also Published As

Publication number Publication date
CN105434465A (zh) 2016-03-30
US10485826B2 (en) 2019-11-26
WO2017101536A1 (zh) 2017-06-22
US20200085863A1 (en) 2020-03-19
US20180000860A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
CN105434465B (zh) 一种防治关节炎的药物组合物及其制备方法
JP6375037B2 (ja) 生薬等含有医薬組成物（肆）
CN102698254B (zh) 一种增加骨密度的组合物，含其制剂及其制备方法
EP0235417A1 (en) Inorganic mineral composition
CN101647815A (zh) 一种动物骨的仿生酶解产物及其用途
CN104605226A (zh) 一种具有增加骨密度功能的保健品
CN102846667A (zh) 一种经低温干燥制备纳米美洲大蠊的制备方法
CN108354898A (zh) 一种治疗类风湿性关节炎的透皮给药制剂及其制备方法
CN103006712A (zh) 一种抗氧化清除自由基的蜂产品提取物
CN101590167A (zh) 一种用于治疗痛风的中药组合物及其制备方法
CN102988422A (zh) 美洲大蠊纳米提取物及其制备方法
CN102949712A (zh) 一种治疗肿瘤疾病的中西复合药物
CN107114775B (zh) 一种基于鮸鱼鱼鳔多肽的降血脂复配物及其制备方法
WO2017181373A1 (zh) 贻贝粘蛋白产品及其抑制软组织炎症的应用
CN110876796A (zh) 一种用于治疗痛风急性发作的中药组合物及其制备方法和应用
CN110917209A (zh) 含硒化合物或硒纳米在制备治疗关节炎药物的注射剂或微针中的用途
CN110101679A (zh) 海藻小苏打微泡腾片及其制备方法和应用
CN109044974A (zh) 包覆维生素d和维生素k的纳米囊泡制剂及其应用
CN104000925B (zh) 一种治疗甲状腺肿大的药物组合物及其应用
CN106511394A (zh) 九香虫脂肪油提取物的新用途
CN107412223A (zh) 一种含氧杂环化合物的医药用途
CN109381466A (zh) 促进糖尿病病人伤口愈合的治疗剂
CN102641472B (zh) 一种治疗骨质疏松症的中药制剂
CN105395574A (zh) 一种药食两用防治心脑血管病复方角鲨烯鱼油软胶囊
CN114366764A (zh) 一种提高人体免疫力，预防和/或治疗骨关节炎的组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220328

Address after: 610041 No. 4, floor 6, building 1, No. 9, Keyuan South Road, high tech Zone, Chengdu, Sichuan

Patentee after: CHENGDU ANPRO BIOTECHNOLOGY Co.,Ltd.

Address before: 610000 No. 16, unit 5, No. 56, Zijing South Road, high tech Zone, Chengdu, Sichuan

Patentee before: Mi Jun

TR01 Transfer of patent right